Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib

The Breakthrough Therapy Designation is based on data from the Phase 1 RMC-6291-001 clinical trial evaluating elironrasib monotherapy in patients with advanced KRAS G12C solid tumors. Results from the trial have demonstrated highly competitive antitumor activity, including differentiated safety and tolerability along with a compelling objective response rate and progression-free survival. "There continues to be a need for new targeted therapies for patients with RAS-addicted cancers, and this Breakthrough T ...